Navigation Links
Steroids to treat asthma: How safe are they?
Date:2/23/2011

This release is available in French.

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit de Montral. These findings, published in this month's issue of Pediatric Allergy, Immunology and Pulmonology, have implications for asthmatic children who have flare-ups and who may be exposed to new contagious diseases.

"There is no question that the administration of corticosteroids reduces the risk and duration of hospital admission in children with acute asthma remain the most effective treatment for moderate and severe asthma exacerbations," says first author Francine M. Ducharme, a Universit de Montral professor and paediatrician and researcher at the Sainte-Justine University Hospital Research Center. "However, the safety profile of these medications continues to raise concerns among parents and physicians. New concerns over their possible impact on the immune system stem from rare reports linking or severe chickenpox infections linked with corticosteroid administration."

Reduced immune response to new triggers

Ducharme and colleagues evaluated the immune response of children aged 3 to 17 years, who had arrived at the emergency department (ED) with an asthma attack. All subjects were given immune triggers (known as antigens) and the immune response between those who received corticosteroids versus those who did not were compared.

"Several corticosteroid-treated children had a significantly lower immune response, as measured by the amount of antibody produced, than non-treated kids," says Ducharme.

Reduced immunity only transient

Children enrolled in the study were revaccinated with the antigen five weeks following their initial ED visit. Comparable immune responses were measured in children exposed to oral corticosteroids and not exposed to corticosteroids.

"These findings indicate there is a transient, not sustained, immune suppression in some children exposed to a new antigen at the same time as a corticosteroid administration," says Ducharme.

"In summary, our finding suggest a transient immune suppression occurs in some children who are concomitantly exposed to a new antigen and corticosteroids during an asthma attack, with a recovery within six weeks."

"Given the high frequency of use of these drugs over the past 20 years, the very rare occurrence of severe infectious disease is reassuring and would suggest that the window of risk is very small and only applies to exposure to a new antigen. However, before prescribing oral corticosteroids, it would appear prudent to systematically enquire about recent exposure to chickenpox in children who did not have chickenpox or the vaccine," adds Ducharme. Moreover, all children with asthma who have not had chickenpox should be vaccinated for this condition.

About asthma

The diagnosis of asthma, which is a chronic inflammatory disease of the lungs, has been significantly on the rise over the last few decades. In 2009, asthma caused approximately 250,000 deaths globally. However, with proper treatment, including the administration of inhaled bronchodilators and corticosteroids, all children with asthma can lead a normal life.

Corticosteroids are anti-inflammatory drugs and are used in asthma to reduce swelling. Strong scientific evidence shows that the use of these medications in patients with moderate to severe acute asthma significantly reduces the rate of hospitalizations and, if admitted, the length of stay in hospital. Consequently, these drugs are and should remain the cornerstone of the treatment of an acute asthma exacerbation.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related medicine news :

1. Inhaled steroids increase diabetes risk, say Lady Davis Institute researchers
2. IV Steroids May Be Overkill in COPD Patients
3. Fountain of youth steroids could protect against heart disease
4. Study finds post-transplant patients off steroids have fewer cardiovascular events
5. Steroids Could Harm Hearts Pumping Ability
6. Nanotechnology may lead to new treatment of liver cancer
7. Racial and ethnic minority adolescents less likely to receive treatment for major depression
8. Specialized blood plasma treatment does not improve rotator cuff healing, study finds
9. New Eye Treatment May Save Preemies Sight
10. Smoking during radiation treatments reduces chance of overall survival
11. Research presented at 2011 GU Cancers Symposium highlights advances in treatment of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: